# Tabectedin to Treat Children and Adolescents With Cancer

> **NCT01453283** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])

## Key facts

- **NCT ID:** NCT01453283
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-20
- **Primary completion:** 2011-10-11
- **Final completion:** 2011-10-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01453283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01453283, "Tabectedin to Treat Children and Adolescents With Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01453283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*